New twists in the AXL(e) of tumor progression

Balazs Halmos; Eric B. Haura

doi:10.1126/scisignal.aai7619

New twists in the AXL(e) of tumor progression

Balazs Halmos, Eric B. Haura

Oncology

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients.

Original language	English (US)
Article number	fs14
Journal	Science Signaling
Volume	9
Issue number	448
DOIs	https://doi.org/10.1126/scisignal.aai7619
State	Published - Oct 4 2016

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Cell Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1126/scisignal.aai7619

Cite this

@article{cdb7610119e844c59967424e1118dc94,

title = "New twists in the AXL(e) of tumor progression",

abstract = "Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients.",

author = "Balazs Halmos and Haura, {Eric B.}",

note = "Publisher Copyright: {\textcopyright} The Authors, some rights reserved.",

year = "2016",

month = oct,

day = "4",

doi = "10.1126/scisignal.aai7619",

language = "English (US)",

volume = "9",

journal = "Science Signaling",

issn = "1945-0877",

publisher = "American Association for the Advancement of Science",

number = "448",

}

TY - JOUR

T1 - New twists in the AXL(e) of tumor progression

AU - Halmos, Balazs

AU - Haura, Eric B.

N1 - Publisher Copyright: © The Authors, some rights reserved.

PY - 2016/10/4

Y1 - 2016/10/4

N2 - Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients.

AB - Patients with a mesenchymal subtype of ovarian cancer face a poor prognosis with limited treatment options to halt metastatic progression. In this issue of Science Signaling, Antony et al. found that the kinase AXL drives the mesenchymal gene signature and motility of ovarian tumor cells. AXL inhibitors may thus slow tumor progression in this subset of patients.

UR - http://www.scopus.com/inward/record.url?scp=84990210511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990210511&partnerID=8YFLogxK

U2 - 10.1126/scisignal.aai7619

DO - 10.1126/scisignal.aai7619

M3 - Article

C2 - 27703029

AN - SCOPUS:84990210511

SN - 1945-0877

VL - 9

JO - Science Signaling

JF - Science Signaling

IS - 448

M1 - fs14

ER -

New twists in the AXL(e) of tumor progression

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this